Christopher Rohde
Gründer bei Factor Bioscience, Inc.
Ursprung des Netzwerks ersten Grades von Christopher Rohde
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA.
1
| Private Company | Miscellaneous Commercial Services | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Christopher Rohde
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Princeton University | College/University | Undergraduate Degree | |
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder | |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Medical/Nursing Services | Founder | |
ETERNA THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer |
Statistik
International
Vereinigte Staaten | 6 |
Sektoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Health Services | 2 |
Operativ
Director/Board Member | 3 |
Founder | 3 |
Chief Executive Officer | 3 |
Corporate Secretary | 2 |
President | 2 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Matthew Angel | 6 |
- Börse
- Insiders
- Christopher Rohde
- Unternehmensverbindungen